AP2886A - 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders - Google Patents

6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders

Info

Publication number
AP2886A
AP2886A AP2010005357A AP2010005357A AP2886A AP 2886 A AP2886 A AP 2886A AP 2010005357 A AP2010005357 A AP 2010005357A AP 2010005357 A AP2010005357 A AP 2010005357A AP 2886 A AP2886 A AP 2886A
Authority
AP
ARIPO
Prior art keywords
treatment
related disorders
derivatives useful
cancer related
quinazoline derivatives
Prior art date
Application number
AP2010005357A
Other languages
English (en)
Other versions
AP2010005357A0 (en
Inventor
Prasad Ramanadham Jyothi
Kali Satya Bhujanga Rao Adibhatla
Rao Bollepalli Nageshwara
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of AP2010005357A0 publication Critical patent/AP2010005357A0/en
Application granted granted Critical
Publication of AP2886A publication Critical patent/AP2886A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2010005357A 2008-01-18 2008-01-18 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders AP2886A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000036 WO2009090661A1 (en) 2008-01-18 2008-01-18 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders

Publications (2)

Publication Number Publication Date
AP2010005357A0 AP2010005357A0 (en) 2010-08-31
AP2886A true AP2886A (en) 2014-05-31

Family

ID=39769348

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005357A AP2886A (en) 2008-01-18 2008-01-18 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders

Country Status (27)

Country Link
US (5) US8143250B2 (pt)
EP (2) EP3012251B1 (pt)
JP (1) JP2011509995A (pt)
KR (2) KR101640161B1 (pt)
CN (1) CN101918374A (pt)
AP (1) AP2886A (pt)
AU (1) AU2008347940A1 (pt)
BR (1) BRPI0822012A2 (pt)
CA (1) CA2711737C (pt)
CY (1) CY1118193T1 (pt)
DK (2) DK3012251T3 (pt)
EA (1) EA018514B1 (pt)
ES (2) ES2593321T3 (pt)
HR (1) HRP20161522T1 (pt)
HU (1) HUE030640T2 (pt)
IL (1) IL207046A (pt)
LT (1) LT2229369T (pt)
MA (1) MA32081B1 (pt)
MX (1) MX2010007852A (pt)
NZ (1) NZ586946A (pt)
PL (1) PL2229369T3 (pt)
PT (1) PT2229369T (pt)
SG (1) SG187490A1 (pt)
SI (1) SI2229369T1 (pt)
UA (1) UA101010C2 (pt)
WO (1) WO2009090661A1 (pt)
ZA (1) ZA201005116B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918374A (zh) * 2008-01-18 2010-12-15 纳特科制药有限公司 用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
CN101857618B (zh) * 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
CN103874696B (zh) * 2011-10-12 2015-06-03 苏州韬略生物科技有限公司 作为激酶抑制剂的喹唑啉衍生物及其使用方法
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
US9546179B2 (en) * 2011-12-20 2017-01-17 Wei Qian Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
ES2899145T3 (es) * 2017-04-15 2022-03-10 Natco Pharma Ltd Un proceso mejorado para la preparación de diclorhidrato de N-(3-etinilfenil)-7-metoxi-6-(3-morfolinopropoxi)quinazolin-4-amina
CN111499577A (zh) * 2019-01-30 2020-08-07 华东师范大学 邻二苯基取代五元含氮芳杂环类类化合物及其应用
AU2022291015A1 (en) 2021-06-10 2023-12-21 Natco Pharma Limited Egfr inhibitor for the treatment of head and neck cancer
CN115518071B (zh) * 2021-06-24 2024-03-19 中国人民解放军联勤保障部队第九〇一医院 一种化合物在制备抗食管癌的药物中的应用
WO2024121861A1 (en) * 2022-12-08 2024-06-13 Natco Pharma Limited Egfr inhibitor for the treatment of head and neck cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US20070020261A1 (en) * 2005-07-22 2007-01-25 Sliwkowski Mark X Combination therapy of her expressing tumors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US690221A (en) 1901-06-20 1901-12-31 Frederik Christian Viggo Arp Stand for cycles.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2005070909A1 (en) 2004-01-22 2005-08-04 Natco Pharma Limited An improved process for the preparation of gefitinib
WO2006090413A1 (en) 2005-02-23 2006-08-31 Natco Pharma Limited Novel crystalline form of gefitinib and a process for its preparation
WO2007060691A2 (en) 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
CN101918374A (zh) * 2008-01-18 2010-12-15 纳特科制药有限公司 用于治疗癌症相关病症的6.7-二烷氧基喹唑啉衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US20070020261A1 (en) * 2005-07-22 2007-01-25 Sliwkowski Mark X Combination therapy of her expressing tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARKINSON T. ET AL.: "An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeflcient. mouse model" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 74, no. 1, 13 March 2007 (2007-03-13), pages 43-50 *

Also Published As

Publication number Publication date
ES2642159T3 (es) 2017-11-15
PL2229369T3 (pl) 2017-01-31
US20150141421A1 (en) 2015-05-21
UA101010C2 (ru) 2013-02-25
CY1118193T1 (el) 2017-06-28
US8921362B2 (en) 2014-12-30
AP2010005357A0 (en) 2010-08-31
EA018514B1 (ru) 2013-08-30
KR101762306B1 (ko) 2017-07-27
DK3012251T3 (en) 2017-10-09
EP3012251B1 (en) 2017-08-30
BRPI0822012A2 (pt) 2015-07-21
HRP20161522T1 (hr) 2017-02-10
DK2229369T3 (en) 2016-12-12
NZ586946A (en) 2012-06-29
WO2009090661A1 (en) 2009-07-23
KR20160086969A (ko) 2016-07-20
KR20100121468A (ko) 2010-11-17
US9481655B2 (en) 2016-11-01
ZA201005116B (en) 2011-03-30
WO2009090661A9 (en) 2010-06-17
EP3012251A1 (en) 2016-04-27
PT2229369T (pt) 2016-11-24
ES2593321T3 (es) 2016-12-07
US20110034459A1 (en) 2011-02-10
CA2711737C (en) 2015-03-31
MA32081B1 (fr) 2011-02-01
HUE030640T2 (en) 2017-06-28
AU2008347940A1 (en) 2009-07-23
LT2229369T (lt) 2016-09-26
CN101918374A (zh) 2010-12-15
EA201001173A1 (ru) 2011-04-29
SI2229369T1 (sl) 2016-11-30
EP2229369B1 (en) 2016-08-17
EP2229369A1 (en) 2010-09-22
JP2011509995A (ja) 2011-03-31
KR101640161B1 (ko) 2016-07-15
US20110039844A1 (en) 2011-02-17
US20170079983A1 (en) 2017-03-23
CA2711737A1 (en) 2009-07-23
US8143250B2 (en) 2012-03-27
IL207046A0 (en) 2010-12-30
IL207046A (en) 2015-09-24
US20190201408A1 (en) 2019-07-04
SG187490A1 (en) 2013-02-28
MX2010007852A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
AP2886A (en) 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
ZA201204658B (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
HUE043569T2 (hu) Vegyületek rák kezelésére
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
ZA201006752B (en) Spiro-indole derivatives for the treatment of parasitic disease
EP2224919A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
IL226362A0 (en) compounds, and methods for treating cancer
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
IL205339A0 (en) Compounds and methods for the treatment of cancer
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
GB0604114D0 (en) Combinations for the treatment of cancer
ZA201000400B (en) Methods and compositions for the treatment of cancer, tumors, and tumor related disorders
HK1139937A (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders